Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused by NF1 loss. While inhibitors of the ERK activating kinases MEK1/2 are promising as a means to treat NF1, the broad blockade of the ERK pathway produced by this strategy is potentially associated with therapy limiting toxicities. Here, we have sought targets offering a more narrow inhibition of ERK activation downstream of NF1 loss in the skeleton, finding that MEKK2 is a novel component of a noncanonical ERK pathway in osteoblasts that mediates aberrant ERK activation after NF1 loss. Accordingly, despite mice with conditional deletion of Nf1 in mature osteoblasts (Nf1fl/fl;Dmp1-Cre) and Mekk2−/− each displaying skeletal defects, Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice show an amelioration of NF1-associated phenotypes. We also provide proof-of-principle that FDA-approved inhibitors with activity against MEKK2 can ameliorate NF1 skeletal pathology. Thus, MEKK2 functions as a MAP3K in the ERK pathway in osteoblasts, offering a potential new therapeutic strategy for the treatment of NF1.
Neurofibromatosis type I (NF1) is an autosomal dominant disorder with an incidence of 1/3500, and ~50% of patients with NF1 display skeletal manifestations including craniofacial dysmorphogenesis, osteopenia/osteoporosis, and impaired fracture healing, including congenital pseudoarthroses. The NF1 gene product, neurofibromin, is a Ras GTPase-activating protein that functions as a negative regulator of Ras/ERK signaling in the development and growth of a variety of tissues1. Loss-of-function mutations in NF1 result in hyperactivation of several signaling pathways, prominently including the MEK/ERK pathway, and preclinical studies indicate utility for MEK/ERK pathway inhibition for treating skeletal and other organ manifestations of NF12,3,4. Along these lines, ERK pathway inhibitors have recently been shown to have clinical utility for the treatment of a subset of plexiform neurofibromas in NF15. Despite this promise, studies of ERK pathway inhibition in other clinical contexts suggest that it can be associated with serious and likely therapy limiting toxicities in a subset of patients, prominently cardiovascular complications including myocardial infarction, heart failure, cardiomyopathy, and hypertension6,7,8. These toxicities are likely intrinsic to the broad importance of the ERK/MAPK pathway in controlling fundamental cellular processes such as proliferation and survival. Toxicity concerns are exacerbated when considering that therapy for skeletal manifestations of NF1 would most plausibly entail long-term or even lifelong treatment. Moreover, profound blockade of ERK pathway activity is associated with severe osteopenia, raising concerns that nonselective ERK pathway inhibition could actually exacerbate skeletal pathology in NF1, or at least that ERK pathway inhibition is expected to have a narrow therapeutic window with regards to skeletal endpoints9,10,11. To overcome these limitations, more selective approaches are needed to target pathways mediating the downstream effects of NF1 loss-of-function.
MAPKs operate in a three-tiered cascade: MAP kinase kinase kinases (MAP3K), MAP kinase kinases (MAP2K), and MAPKs. While the connections between MAP2Ks and MAPKs largely occur in a stereotypical and invariant manner, the connections between MAP3Ks and downstream MAP2Ks are much more context-dependent, differing both among cell types and with respect to specific stimuli. This suggests that inhibition of MAP3Ks may offer a more selective and ultimately less toxic means than directly targeting MAP2Ks or MAPKs to inhibit the aberrant ERK pathway activation occurring downstream of NF1 loss-of-function. While MAP3Ks contributing to p38 and JNK activation in osteoblasts, including ASK1 (MAP3K5)12 and TAK1 (MAP3K7)13,14, have been identified, the MAP3K mediating ERK activation in osteoblasts is largely unknown, aside from studies showing that MLK3 (MAP3K11) contributes to both ERK and p38 activation and a study of RAF isoforms largely focused on cartilage15,16. MEKK2 (MAP3K2) is a member of the MEK kinase group of MAP3Ks, and early in vitro studies demonstrated that MEKK2 has the ability to activate a number of downstream MAPK pathways, including ERK1/2, JNK, p38, and ERK517,18,19,20,21. We previously observed that MEKK2 mediated an alternative pathway for the deubiquitination and stabilization of β-catenin in osteoblasts and that MEKK2-deficient mice display significant cortical and trabecular osteopenia due to impaired osteoblast activity22.
Here we identify MEKK2 as a MAP3K contributing to ERK pathway activation in osteoblasts and show that loss of MEKK2 is sufficient to prevent the constitutive ERK activation occuring in models of skeletal NF1. Accordingly, loss of MEKK2 can ameliorate the skeletal manifestations occuring in a mouse model of skeletal NF1. We also show that ponatinib, an FDA-approved tyrosine-kinase inhibitor, can inhibit MEKK2 and that administration of ponatinib significantly improves skeletal pathology in a mouse model of skeletal NF1. This provides proof-of-principle for targeting MEKK2 as a strategy for the management of the skeletal manifestations of NF1.
MEKK2 mediates ERK activation downstream of NF1 loss-of-function
Given the ability of MEKK2 to activate the ERK pathway in previous overexpression studies conducted in a non-skeletal context17,21, we considered it as a candidate MAP3K mediating ERK activation in osteoblasts. Immunoblotting showed that ERK1/2 activation was markedly reduced in primary Mekk2−/− calvarial osteoblasts (COBs), and, accordingly, that phosphorylation of the well-characterized ERK substrates RSK2 and GSK3β was also reduced (Fig. 1a). RSK2 is known to in turn phosphorylate and activate ATF4, a critical transcription factor regulating the later stages of osteoblast differentiation23. Consistent with this reduction in RSK2 activation, Mekk2−/− COBs showed reduced activity of the ATF4-responsive osteoblast-specific cis-acting element 1 (OSE1)-luciferase reporter plasmid (Fig. 1b). To provide direct biochemical confirmation of the ability of MEKK2 to mediate ERK pathway activation, an in vitro kinase assay was performed, showing that recombinant MEKK2 directly phosphorylated MEK1 and MEK2 (Fig. 1c). Thus, MEKK2 contributes to basal ERK activation, and NF1 loss-of-function via lentiviral Cre deletion in Nf1fl/fl osteoblasts induces aberrant ERK activation (Fig. 1d). To examine aberrant ERK activation downstream of NF1 loss-of-function in vivo, we generated mice with a conditional deletion of Nf1 in mature osteoblasts using dentin matrix acidic phosphoprotein 1-Cre (Dmp1-Cre)24. Consistent with in vitro results, ERK was highly activated in osteoblasts in the femurs of Nf1fl/fl;Dmp1-Cre mice compared to Nf1fl/fl controls (Fig. 1e). We next examined if MEKK2 mediates ERK activation downstream of NF1 loss-of-function. Previously, we observed that FGF2 strongly activates MEKK2 phosphorylation in osteoblasts22. Indeed, knockdown of NF1 in human mesenchymal stromal cell-derived osteoblasts resulted in enhanced MEKK2 phosphorylation in response to FGF2, showing that loss of NF1 can enhance MEKK2 activation (Fig. 1f). Similarly, transduction of Nf1fl/fl osteoblasts with lentiviral Cre increased MEKK2 phosphorylation as shown by either use of a phos-tag gel or immunoblotting with anti-p-MEKK2 antibodies (Fig. 1g). Immunohistochemistry for p-MEKK2 levels in cortical bone was performed, finding that Nf1fl/fl;Dmp1-Cre mice showed greater positivity for p-MEKK2-within bone adjacent mesenchymal cells (Fig. 1h). Likewise, knockdown of Nf1 enhanced ERK activation by FGF2, and this enhancement was rescued by additional knockdown of Mekk2 (Fig. 1i). Thus, MEKK2 contributes to the aberrant hyperactivation of ERK occurring with NF1 loss-of-function in vitro.
MEKK2 deficiency rescues NF1-associated skeletal phenotypes
Previously, Nf1fl/fl;Dmp1-Cre mice have been reported as a model of skeletal NF1, finding that they display spontaneous fractures, accompanied by reduced mechanical strength, low bone mineral density, and high cortical porosity with an osteomalacia-like bone phenotype25. Use of the Dmp1-Cre here has the advantage that it avoids the severe growth and joint dysplasia phenotypes associated with the deletion of NF1 in early osteoprogenitors/skeletal stem cells as seen with Prx1 or Col2-Cre, which may complicate interpretation of genetic or pharmacologic rescue experiments26,27. In line with prior reports, we observed that Nf1fl/fl;Dmp1-Cre mice display high cortical porosity and uneven deposition of endosteal cortical bone. Based on our in vitro findings, we hypothesized that additional deficiency for MEKK2 will ameliorate these phenotypes in Nf1fl/fl;Dmp1-Cre mice. Indeed, despite Mekk2−/− mice themselves being osteopenic and having impaired bone formation, Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice displayed a substantial rescue of the Nf1fl/fl;Dmp1-Cre phenotype, with normalization of cortical architecture and porosity (Fig. 2a, b), trabecular osteopenia (Fig. 2c, d) and calvarial hypomineralization (Fig. 2e). In keeping with this, levels of P1NP (procollagen type 1 N-terminal propeptide), a marker for bone formation and osteoblast activity, were greatly increased in Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice compared to Nf1fl/fl;Dmp1-Cre mice, whereas no significant difference was observed in levels of CTX (Collagen type I C-terminal telopeptide), a marker of osteoclast activity28. Similarly, FGF23, 25(OH) vitamin D, and phosphate levels were all normalized in Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice relative to Nf1fl/fl;Dmp1-Cre mice (Fig. 2f). Consistent with in vitro observations of MEKK2 acting downstream of NF1 loss-of-function to mediate ERK pathway activation, immunostaining confirmed that p-MEKK2, p-MEK1, and p-ERK1/2 levels were strongly decreased in osteoblasts in femurs of Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice compared to Nf1fl/fl;Dmp1-Cre mice (Fig. 2g). p-AKT levels were also analyzed by immunostaining, but there were no significant differences among these mice (Supplementary Fig. 1a). To explore impacts on the osteocyte dendritic network, we performed filamentous actin (F-actin) staining, finding clear disruption of the osteocyte dendritic network in Nf1fl/fl;Dmp1-Cre mice. However, this aspect of the NF1 loss-of-function phenotype did not show a substantial degree of rescue by additional MEKK2 deficiency (Supplementary Fig. 1b). Thus, deficiency for MEKK2 ameliorates a wide range of NF1-associated skeletal phenotypes in mice.
Ponatinib inhibits MEKK2 and ameliorates NF1 phenotypes
Given this rescue, we hypothesized that pharmacological inhibition of MEKK2 could have clinical utility in treating the skeletal manifestations of NF1. To maximize the translational relevance of this study, we focused on identifying whether well-studied and FDA-approved kinase inhibitors had activity against MEKK2, focusing on a set of compounds previously studied in cell-free assays with MEKK2, including AT9283, crizotinib, ponatinib, and bosutinib29,30. By immunoblotting, we observed that ponatinib strongly reduced MEKK2 phosphorylation (Fig. 3a–c) and further observed that ERK activation was completely inhibited by AT9283 and ponatinib in response to FGF2 (Fig. 3d, e). An in vitro kinase assay using purified recombinant proteins confirmed that ponatinib inhibited both MEKK2 autophosphorylation and MEKK2-mediated MEK1 phosphorylation in a dose-dependent manner with an IC50 of ~100 nM (Fig. 3f). To examine whether ponatinib phenocopies the effects of Mekk2 knockdown, mRNA levels were analyzed in NF1-deficient osteoblasts during in vitro differentiation. Osteoblast-related genes, including Osx, Runx2, Bsp, and Ocn were measured, demonstrating that either Mekk2 knockdown or ponatinib treatment both rescued or increased expression of osteoblast marker genes (Fig. 3g).
To strengthen the evidence that these in vitro effects of ponatinib to block MEKK2-mediated ERK pathway activation downstream of NF1 loss-of-function truly reflect inhibition of MEKK2, a compound with a distinct chemical scaffold expressly identified as a MEKK2 inhibitor was examined (BRITE-719)31. BRITE-719 had similar effects to those of ponatinib, strongly inhibiting ERK phosphorylation (Fig. 3h). BRITE-690, an analog of BRITE-719 lacking MEKK2 inhibitory activity, showed no impact in these assays, further confirming that the effects observed reflect inhibition of MEKK2.
After validating that ponatinib has the activity to inhibit MEKK2, we next examined whether ponatinib can rescue the skeletal phenotypes of Nf1fl/fl;Dmp1-Cre mice. To do this, we administered ponatinib intraperitoneally in 11-week-old Nf1fl/fl;Dmp1-Cre mice for 5 weeks. Similar to the effect of additional MEKK2 deficiency on the Nf1fl/fl;Dmp1-Cre phenotype, ponatinib-treated Nf1fl/fl;Dmp1-Cre mice displayed a clear rescue of defects in cortical bone architecture (Fig. 4a, b), trabecular osteopenia (Fig. 4c, d), and calvarial hypomineralization (Fig. 4e and Supplementary Fig. 2) as compared to the vehicle group. Similarly, ponatinib treatment elevated P1NP, 25(OH) vitamin D, and phosphate levels relative to the levels in vehicle-treated Nf1fl/fl;Dmp1-Cre mice (Fig. 4f). Similar to observations made in vitro, Nf1fl/fl;Dmp1-Cre mice following administration of ponatinib displayed significantly lower levels of p-MEKK2, p-MEK1, and p-ERK1/2 in osteoblasts compared to vehicle controls (Fig. 4g), but p-AKT levels were not changed (Supplementary Fig. 3a). Osteocyte dendritic network morphology was examined, but there was no clear evidence that ponatinib rescued this aspect of the NF1 loss-of-function phenotype (Supplementary Fig. 3b). As it may be clinically useful to target NF1-related skeletal therapies to discrete temporal windows, such as times of skeletal crisis, including fracture nonunion, or to critical windows in skeletal development, the durability of ponatinib effects were examined. Ponatinib treatment was initiated at 4 weeks of age, continued for 5 weeks, and then a phenotypes were assessed 7 weeks after drug withdrawal. Ponatinib treatment had durable effects that persist after treatment withdrawal under these conditions, including effects to ameliorate cortical defects, though, as expected, the magnitude of these effects was weaker than that seen with ponatinib treatment continuing until the experimental endpoint (Supplementary Fig. 4a–c). Taken together, these findings suggest that MEKK2 is a key MAP3K-mediating ERK activation in osteoblasts and that MEKK2 is a potential target for NF1 treatment.
We here demonstrate rescue of the Nf1fl/fl;Dmp1-Cre phenotype through genetic or pharmacologic inhibition of MEKK2. NF1 deficiency induces MEKK2 activation along with abnormal ERK activation, and MEKK2 contributes to the aberrant ERK activation seen with NF1 loss-of-function via the ability of MEKK2 to activate MEK1/2. MEKK2 also contributes to basal ERK activation, indicating that pathways other than those mediated by canonical RAF isoforms play key roles in ERK activation in osteoblasts. Despite Mekk2−/− mice displaying a low bone mass phenotype, additional MEKK2 deficiency in osteoblast-specific NF1-deficient mice dramatically improves NF1 skeletal phenotypes, including cortical bone porosity, trabecular bone mass, and endocrine disruptions related to calcium and phosphate homeostasis. Finding evidence that two loss-of-function alleles, each with strong deleterious phenotypes individually result in a phenotype markedly less severe than either alone when crossed provides clear evidence of epistasis, and therefore support for the biochemical model that MEKK2 here acts as a downstream mediator of the effects of NF1 deficiency in osteoblasts. We also note that, while there are several models of skeletal neurofibromatosis, each generated using different cre lines and with different features, several of the MEKK2 or ponatinib-dependent endpoints examined here, such as the cortical porosity/endocortical pitting phenotype, are shared across several models, including Nf1fl/fl;Prx-Cre26, Nf1fl/fl;Col2-Cre27, and Nf1fl/fl;Osx-Cre32 mice, providing support for these findings having relevance beyond the specific Dmp1-Cre based model utilized here.
We here provide proof-of-concept that ponatinib (previously known as AP24534) can ameliorate skeletal pathology associated with NF1. In addition to the data offered in this study, support for the proposed mechanism of ponatinib mediating its effects through ERK pathway inhibition comes from studies finding that MEK1/2 inhibition promoted bone healing in the context of NF1 deficiency2,33. Many NF1-associated skeletal phenotypes, except alterations in CTX levels, are rescued by ponatinib or MEKK2 deficiency. CTX levels not being regulated by MEKK2 is consistent with observations that, despite showing robust skeletal phenotypes, ablation of the ERK pathway in osteoblast lineage cells does not significantly alter CTX levels9. Further work has reported that MEK1/2 inhibition suppressed abnormal expression of genes regulating PPi homeostasis in NF1-deficient osteoblasts32. Thus, the findings here are broadly consistent with the role of the ERK pathway in the skeletal pathogenesis of NF1.
Ponatinib is currently approved by the FDA for patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), particularly patients with tumors bearing the BCR-ABL T315I resistance mutation, suggesting that currently approved drugs may have an activity to ameliorate skeletal manifestations of NF134. The clinical feasibility of using a MEKK2 inhibitor, either ponatinib or an alternative with increased specificity for MEKK2, is supported by observing that early treatment of mice produces a relatively durable amelioration of the phenotype that is maintained for several weeks after treatment discontinuation. Chemically, the activity of ponatinib against MEKK2 observed here is overall consistent with observations that ponatinib displays relatively broad tyrosine-kinase activity, including against FGFR, VEGFR, PDGFR, FLT3, and c-Src, and it is possible or even probable that inhibition of non-MEKK2 targets, or other unexpected mechanisms of ponatinib, could have important contributions to the overall skeletal effects of ponatinib observed here34,35,36. However, support for MEKK2 being at least one relevant target of ponatinib comes from finding a very similar rescue of the Nf1fl/fl;Dmp1-Cre phenotype with either ponatinib treatment or additional MEKK2 deficiency. Additional support comes from observing that a small molecule inhibitor of MEKK2 with a distinct chemical scaffold from ponatinib, but not an analog of this compound lacking MEKK2 activity, recapitulates some of the in vitro effects of ponatinib on ERK activation downstream of NF1 loss-of-function31.
However, any therapeutic promise of ponatinib must be balanced against its toxicities, particularly concerns that ponatinib is associated with increased risk of arterial and venous thrombosis in CML patients37. Given the broad tyrosine-kinase activity of ponatinib, it is plausible or even likely that these toxicities may be associated with ponatinib targets other than MEKK2, suggesting that generation of analogs or novel chemotypes with improved relative selectivity for MEKK2 over other tyrosine kinases may allow the potential therapeutic effect of ponatinib to be chemically dissected away from limiting toxicities. Alternatively, strategies that focus on only providing transient therapy to resolve the most severe clinical sequelae, such as persistent nonunion after fracture, may offer a means to favorably balance the benefits and toxicities of these agents. Support for this strategy comes from studies that MEK1/2 inhibition can promote healing after fracture in models of NF12,20. Additional support comes from observing that the effects of ponatinib persist for several weeks after therapy discontinuation, raising the possibility that either intermittent or crisis-targeted MEKK2 inhibition could have relatively durable overall effects on NF1-associated skeletal phenotypes extending beyond the period of treatment. Any consideration of the toxicities of either ponatinib or MEKK2 inhibition should be considered relative to alternative strategies, such as the broad ERK pathway inhibition associated with MEK inhibitors such as trametinib, which is potentially associated with cardiomyopathy, hepatic toxicity, hypertension, rash, and interstitial lung disease38. Both further preclinical and clinical studies will be needed to explore these issues and determine the potential utility of either ponatinib or alternative kinases inhibitors with increased MEKK2 selectivity. Additionally, as NF1 is a multisystem disorder, any novel therapeutic agent would have to be integrated into a comprehensive strategy for management of these complex patients.
We here identify MEKK2 as a mediator of aberrant ERK activation in NF1-deficient mature osteoblasts. To the degree that ERK is also implicated in the pathogenesis of other non-skeletal manifestations of NF1, including benign neurofibromas and malignant peripheral nerve sheath tumors39, this suggests that evaluating the relative contributions of RAF isoforms versus MEKK2 in these non-skeletal contexts and potential therapeutic relevance of MEKK2 inhibition is warranted. Conversely, while there is evidence that ERK is a key mediator of skeletal and non-skeletal manifestations of NF1, several other pathways are activated downstream of NF1 loss-of-function, including PKA40,41. It will be of interest to determine whether MEKK2 contributes to the activation of these non-ERK pathways downstream of NF1 and also determine how inhibition of these alternative pathways may contribute to NF1 therapy. MEKK2-independent pathways acting downstream of NF1 are likely responsible for the few aspects of the Nf1fl/fl;Dmp1-Cre phenotype not rescued by MEKK2 or ponatinib, including alterations in CTX levels or disruption of the osteocyte dendritic network. Given that MEKK2 can directly phosphorylate β-catenin and modulate its stability in osteoblasts and that aberrant β-catenin activation has been proposed as contributing to NF1-associated skeletal pathology22,42, this raises the possibility that, in addition to ERK, β-catenin may also contribute to the therapeutic effects downstream of MEKK2 deficiency or inhibition on NF1.
Floxed Nf1 (Nf1fl/fl) mice (Stock 017639) were purchased from Jackson Laboratories. Generation of the Mekk2−/− mouse strain was described previously43. Transgenic mice expressing Cre recombinase under the control of the Dmp1 promoter (Dmp1-Cre)44 were bred with Nf1fl/fl and/or Mekk2−/− mice. All mice used were backcrossed more than six generations onto the C57BL/6 background. All mice were maintained on a C57Bl6/J background throughout the study. All animals were maintained a 12 hr light/dark cycle, temperatures of 64–79 °F (~18–26 °C) with 40–60% humidity in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were handled according to protocols approved by the Weill Cornell Medical College subcommittee on animal care (IACUC).
Kinase inhibitors used were AT9283 (cat. no. S1134, Selleckchem), crizotinib (PF-02341066) (cat. no. S1068, Selleckchem), ponatinib (AP24534) (cat. no. S1490, Selleckchem), bosutinib (SKI-606) (cat. no. S1014, Selleckchem), BRITE-0600690 (BRITE-690, inactive compound), and BRITE-0600719 (BRITE-719, compound 1s, active compound)31.
Osteoblast culture and differentiation assays
Primary COBs were isolated from 5-day-old neonates by collagenase type II (cat. no. C6885, SigmaMillipore) and dispase II (cat. no. 04942078001, Roche) digestion. Cells were cultured in differentiation medium containing ascorbic acid and β-glycerophosphate. hMSCs were cultured and differentiated into osteoblasts as described by the manufacturer (Lonza). Primary COBs and Saos-2 cells were cultured in α-MEM medium (cat. no. 15-012CV, Cellgro) containing 10% FBS, 2 mM l-glutamine, 1% penicillin/streptomycin, 1% HEPES, and 1% nonessential amino acids and differentiated with ascorbic acid and β-glycerophosphate. All cells were routinely tested to be mycoplasma negative.
µCT analysis was conducted on a Scanco Medical µCT 35 system at the Citigroup Biomedical Imaging Core using the previously described15. Briefly, a Scanco Medical μCT 35 system with an isotropic voxel size of 7 μm was used to image the distal femur. Scans were conducted in 70% ethanol and used an X-ray tube potential of 55 kVp, an X-ray intensity of 0.145 mA, and an integration time of 600 ms. µCT analysis was performed by an investigator blinded to the genotypes of the animals under analysis. All endpoint µCT analysis was carried out on 16-week-old mice.
In vitro kinase assay
In all, 200 ng of recombinant GST-tagged MEKK2 (Dagger, cat. no. M0324, MilliporeSigma and Double dagger, cat. no. PV3822, ThermoFisher) was incubated for 20 min at 30 °C in kinase buffer (20 mM Hepes (pH 7.5), 20 mM MgCl2, 1 mM EDTA, 2 mM NaF,2 mM glycerophosphate, 1 mM DTT, and 10 μM ATP) and 10 μCi of (γ-32P) ATP (cat. no. NEG502H250UC, PerkinElmer) containing unactive GST-tagged MEK1 (cat. no. 14-420, MilliporeSigma), unactive His-tagged MEK2 (cat. no. 14-532, MilliporeSigma), or GST-tagged MEK5 (cat. no. A33380, ThermoFisher). The substrates then were resolved by SDS/PAGE, and phosphorylated proteins were visualized by autoradiography. To assess MEKK2 kinase activity after ponatinib treatment, recombinant proteins were incubated with serially diluted ponatinib for 20 min. Cell-free kinase assay conducted as described above.
Cells were lysed in RIPA lysis buffer (10 mM Tris, 50 mM NaCl, 5 mM EDTA, 2 mM NaF, 30 mM Peptin, 5 μg/ml Aprotinin, and 1% Triton X-100) supplemented protease and phosphatase inhibitor cocktail (cat. no. 78440, ThermoFisher), and the protein concentration was determined by BCA protein assay reagent (cat. no. A53226, ThermoFisher). Proteins were separated by SDS-PAGE and then electrophoretically transferred to PVDF membranes. Membranes were incubated with a blocking buffer followed by incubation with primary and the appropriate secondary antibodies and developed with ECL blotting substrate (cat. no. 32134, ThermoFisher). Primary antibodies used were specific for NF1 (cat. no. A300-140A, BETHYL), MEKK2 (cat. no. A302-163A, BETHYL), ERK1/2 (cat. no. 9102, Cell Signaling Technology), phospho-ERK1/2 (Thr202/Tyr204) (cat. no. 4377, Cell Signaling Technology), AKT (cat. no. 9272, Cell Signaling Technology), phospho-AKT (Thr308) (cat. no. 13038, Cell Signaling Technology), phospho-p38 (Thr180/Tyr182) (cat. no. 9215, Cell Signaling Technology), phospho-RSK (Ser380) (cat. no. 12032, Cell Signaling Technology), phospho-GSK-3β (Ser9) (cat. no. 5558, Cell Signaling Technology), phospho-β-catenin (Ser675) (cat. no. 4176, Cell Signaling Technology), JNK2 (cat. no. 9258, Cell Signaling Technology), phospho-JNK (Thr183/Tyr185) (cat. no. 4668, Cell Signaling Technology), HSP90 (cat. no. sc-515081, Santa Cruz Biotechnology), and GAPDH (cat. no. sc-25778, Santa Cruz Biotechnology). Primary antibodies were detected with goat anti-mouse IgG HRP (cat no. 31430, Invitrogen) and goat anti-rabbit IgG HRP (cat no. 31460, Invitrogen). The generation of the phospho-MEKK2 polyclonal antibody was described previously21. To measure the levels of phosphorylated proteins, a Phos-tag gel (cat. no. 192-18001, Wako) was used according to the manufacturer’s instructions. All uncropped blot images are provided in Supplementary Fig. 5.
In vivo ponatinib treatment
Treatment was initiated in 11-week-old male and female mice. Mice were administered ponatinib (25 mg/kg, intraperitoneal) (cat. no. S1490, Selleckchem) daily for 5 weeks. Ponatinib was first dissolved in DMSO at 100 mg/ml then resuspended in 30% PEG400 + 10% Triton X-100 in PBS. This solution was also used as the vehicle control. To determine the durability of the effects of ponatinib, treating mice starting at 4 weeks of age for 5 weeks and then subsequently waiting 7 weeks before evaluating the phenotypes.
We analyzed mouse-PINP (cat. no. LS-F7173, LSBio), mouse-CTX (cat. no. LS-F21349, LSBio), mouse-FGF23 (cat. no. LS-F31725-1, LSBio), mouse-PTH (cat.no. LS-F23085-1, LSBio), mouse-Phosphate (cat. no. ab65622, Abcam), and mouse-25(OH) Vitamin D (cat. no. ab213966, Abcam) by using a kit. All ELISAs were run according to the manufacturer’s instructions.
For immunofluorescence, femurs were harvested, embedded, and cut into frozen sections, followed by rehydration with PBS. Samples were then incubated with primary antibody against phospho-MEKK2 (Ser520; cat. no. PA5-105898, Invitrogen), phospho-MEK1 (Thr286; cat. no. 9127, Cell Signaling Technology), phospho-ERK1/2 (Thr202/Tyr204; cat. no. 4370, Cell Signaling Technology), phospho-AKT (Ser473; cat. no. 4060, Cell Signaling Technology) overnight at 4 °C, then washed three times with PBS. Secondary antibodies, goat anti-rabbit IgG Alexa fluor 633 (cat no. A-21070, Invitrogen) were added to the sample for 1 h followed by washing three times with PBS. Samples were finally mounted with ProLong Gold antifade reagent with DAPI (cat. no. P36931, Invitrogen). For F-actin staining, fluorescent-conjugated phalloidin was used (cat. no. A12379, Invitrogen). Imaging was performed with a Zeiss LSM 880 with Airyscan high-resolution-detector confocal microscope. All immunofluorescence experiments were quantified by examining at least three independent fields per mouse (n = 3 mice per group). For histological analysis, femurs were dissected from mice, fixed in 4% PFA for 24 h, and decalcified by daily changes of 15% tetrasodium EDTA for 2 weeks and embedded and cut into frozen sections, followed by rehydration with PBS. Decalcified sections were incubated with primary antibodies to phospho-MEKK2 (Ser520) (cat. no. PA5-105898, Invitrogen) overnight at 4 °C and then immunoreactivity was visualized using HRP substrate (cat. no. SK-4805, Vector lab). Methyl green was used as counterstain.
Total mRNA was isolated from calvarial osteoblasts using TRIzol (cat. no. 15596026, Invitrogen), and reverse transcription was performed with the High-Capacity cDNA Reverse Transcription Kit (cat. no. 4368814, Applied Biosystems) according to the manufacturer’s instructions. The primer sequences used in this study are described in Supplementary Table 1.
All data are shown as the mean ± s.d. or mean ± s.e.m. as indicated. For comparisons between two groups unpaired, two-tailed Student’s t tests were used. For comparisons of three or more groups, one-way ANOVA was used if normality tests passed, followed by Tukey’s multiple comparison test for all pairs of groups. GraphPad PRISM v.7.04 was used for statistical analysis. P < 0.05 was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
All relevant data are available from the authors. Source data are provided with this paper.
Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593–604 (2001).
De La Croix Ndong, J. et al. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx−/− mice. J. Bone Miner. Res. 30, 55–63 (2015).
Chang, T. et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J. Clin. Invest. 123, 335–339 (2013).
Staser, K. et al. Normal hematopoiesis and neurofibromin- deficient myeloproliferative disease require Erk. J. Clin. Invest. 123, 329–334 (2013).
Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1–related plexiform neurofibromas. N. Engl. J. Med. 375, 2550–2560 (2016).
Chu, T. F. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011–2019 (2007).
Kerkelä, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908–916 (2006).
Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332–344 (2007).
Kim, J.-M. et al. The ERK MAPK pathway is essential for skeletal development and homeostasis. Int. J. Mol. Sci. 20, 1803 (2019).
Ge, C., Xiao, G., Jiang, D. & Franceschi, R. T. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 176, 709–718 (2007).
Matsushita, T. et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell. Biol. 29, 5843–5857 (2009).
Matsui, H. et al. The expression of Fn14 via mechanical stress-activated JNK contributes to apoptosis induction in osteoblasts. J. Biol. Chem. 289, 6438–6450 (2014).
Greenblatt, M. B. et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J. Clin. Invest. 6, 2457–2473 (2010).
Fukuno, N. et al. TGF-β-activated kinase 1 mediates mechanical stress-induced IL-6 expression in osteoblasts. Biochem. Biophys. Res. Commun. 408, 202–207 (2011).
Zou, W. et al. MLK3 regulates bone development downstream of the faciogenital dysplasia protein FGD1 in mice. J. Clin. Invest. 121, 4383–4392 (2011).
Provot, S. et al. A-Raf and B-Raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol. Cell. Biol. 28, 344–357 (2008).
Blank, J. L., Gerwins, P., Elliott, E. M., Sather, S. & Johnson, G. L. Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. J. Biol. Chem. 271, 5361–5368 (2002).
Schaefer, B. C. et al. Live cell fluorescence imaging of T cell MEKK2: redistribution and activation in response to antigen stimulation of the T cell receptor. Immunity 11, 411–421 (1999).
Su, B., Cheng, J., Yang, J. & Guo, Z. MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression. J. Biol. Chem. 276, 14784–14790 (2001).
Deacon, K. & Blank, J. L. Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)/c-Jun NH 2 -terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3. J. Biol. Chem. 272, 14489–14496 (2002).
Zhang, D. et al. Identification of MEKK2/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways. EMBO J. 25, 97–107 (2006).
Greenblatt, M. B. et al. MEKK2 mediates an alternative β-catenin pathway that promotes bone formation. Proc. Natl Acad. Sci. USA 113, E1226–E1235 (2016).
Yang, X. et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117, 387–398 (2004).
Kalajzic, I. et al. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone 35, 74–82 (2004).
Kamiya, N. et al. Targeted disruption of NF1 in osteocytes increases FGF23 and osteoid with osteomalacia-like bone phenotype. J. Bone Miner. Res. 32, 1716–1726 (2017).
Kolanczyk, M. et al. Multiple roles for neurofibromin in skeletal development and growth. Hum. Mol. Genet. 16, 874–886 (2007).
Wang, W. et al. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum. Mol. Genet. 20, 3910–3924 (2011).
Greenblatt, M. B., Tsai, J. N. & Wein, M. N. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin. Chem. 63, 464–474 (2017).
Ahmad, S., Johnson, G. L. & Scott, J. E. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity. Biochem. Biophys. Res. Commun. 463, 888–893 (2015).
Ahmad, S., Hughes, M. A., Johnson, G. L. & Scott, J. E. Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. J. Biomol. Screen. 18, 388–399 (2013).
Ahmad, S. et al. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2). Biochem. Biophys. Res. Commun. 496, 205–211 (2018).
De La Croix Ndong, J. et al. Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. Nat. Med. 20, 904–910 (2014).
Sharma, R. et al. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurobromin-decient mice. Hum. Mol. Genet. 22, 4818–4828 (2013).
O’Hare, T. et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. https://doi.org/10.1016/j.ccr.2009.09.028 (2009).
Gozgit, J. M. et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer Ther. 10, 1028–1035 (2011).
Choi, J. P. et al. Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations. Sci. Adv. 4, eaau0731 (2018).
Gainor, J. F. & Chabner, B. A. Ponatinib: accelerated disapproval. Oncologist 20, 847–848 (2015).
Welsh, S. J. & Corrie, P. G. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther. Adv. Med. Oncol. 7, 122–136 (2015).
Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123, 340–347 (2013).
Guo, H. F., The, I., Hannan, F., Bernards, A. & Zhong, Y. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 276, 795–798 (1997).
The, I. et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276, 791–794 (1997).
Baht, G. S., Nadesan, P., Silkstone, D. & Alman, B. A. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone 98, 31–36 (2017).
Guo, Z. et al. Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol. Cell. Biol. 22, 5761–5768 (2002).
Lu, Y. et al. DMP1 -Targeted Cre expression in odontoblasts and osteocytes. J. Dent. Res. 86, 320–325 (2007).
This project was supported by a Career Award for Medical Scientists from the Burroughs Wellcome Fund, the NIH under award DP5OD021351 and R01AR075585, the Department of Defense under NF150055. This publication is based on research supported by the Pershing Square Sohn Cancer Research Alliance via an award to M.B.G. This research was supported by the award to D.Y.S. through the Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education (Grant no. 2017R1A6A3A03003075). We thank Graham Su at Yale University, the Research Animal Resource Center (RARC), and the Microscopy and Image Analysis Core Facilities at Weill Cornell Medicine for their technical assistance.
The authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bok, S., Shin, D.Y., Yallowitz, A.R. et al. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I. Nat Commun 11, 5704 (2020). https://doi.org/10.1038/s41467-020-19555-6